The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myeloma
In this presentation, Thierry Facon, MD, Lille University Hospital, Lille, France, shares updates from the Phase III IMROZ trial (NCT03319667), which investigated the safety and efficacy of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
